Pharmaceutical Source Workshop, Session 2 | Antibody Discovery and Drug-likeness Analysis
Release Date:
2023-04-19 13:13
Pharmaceutical Source Research and Development Workshop
Focusing on the fields of biomacromolecules, cell therapy, and gene therapy, this program takes a comprehensive, end-to-end approach to drug discovery and development, addressing key challenges and bottlenecks throughout the entire R&D process. It features carefully designed knowledge modules and invites industry experts to deliver small-scale, in-person presentations, making it a truly focused platform for technical exchange and interaction. This course is designed to provide professionals in the field with a new, in-depth learning opportunity that can be pursued alongside their current work.
Part 01
The in-person classes for the second training session have begun!
After a long hiatus due to the pandemic, the Yaoyuan Society training program is finally underway! “Antibody Discovery and Drugability Analysis” The second session of the in-person specialized training course is officially underway!
Course start date: May 13–14, 2023
Course location: Detailed address will be notified to students via text message before the class begins.
Course fee: Early-bird price before May 1: RMB 2,400 per person 。
Full price will be reinstated after May 1: RMB 3,000 per person 。
Group Booking Benefits: Groups of 3 or more receive a 10% discount, while groups of 5 or more receive an 20% discount (fees include course tickets, training materials, and lunch during the course).
Registration is welcome.
Long-press the QR code to obtain registration information.
Part 02
Course Content Arrangement
1
May 13:
Antibody Discovery: The First Step in Developing Novel Antibody Therapeutics
08:30–10:00 Overview of the Antibody Discovery Platform
10:00–10:30 Tea Break
10:30–12:00 Development and Applications of Phage Display Technology
12:00–13:30 Lunch and rest
13:30–15:00 Development and Application of Antibody Display on the Surface of Mammalian Cells
15:00–15:30 Tea Break
15:30–17:00 Discussion of Case Studies on Antibody Screening Technologies
2
May 14:
Evaluation of Antibody Drug Developability and Drug-likeness:
Bridge Between Antibody Discovery and CMC
08:30–10:00 Overview of the Domestic and International Markets and Development of Antibody Drugs
10:00–10:30 Tea Break
10:30–12:00 Antibody Sequence Analysis
12:00–13:30 Lunch and rest
13:30–15:00 Physicochemical Analysis and Stability Assessment of Antibody Proteins
15:00–15:15 Tea Break
15:30–16:45 Feasibility of CMC Development for Antibody Drugs
Part 03
Guest Biography
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board